Traxis Partners’s Biogen BIIB Stock Holding History

Traxis Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-14,000	Closed	-$3.01M	–	6
2013 Q2	$3.01M	Buy	+14,000	New	+$2.99M	2.33%	9

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Traxis Partners's BIIB Position: Q3 2013 in Review

Traxis Partners sold out of Biogen (BIIB) in Q3 2013, closing a stake of 14,000 shares — an estimated $3.01M sold.

Traxis Partners first reported a position in BIIB in Q2 2013 and held it in 1 quarter. The position peaked at $3.01M in Q2 2013. 656 funds tracked by Wall St. Rank hold BIIB as of Q3 2013.

Traxis Partners reported no remaining Biogen position as of Q3 2013 after selling out during the quarter.
Traxis Partners sold 14,000 Biogen shares in Q3 2013, an estimated $3.01M.
Traxis Partners first reported a position in Biogen in Q2 2013 and held it in 1 quarter.
Traxis Partners's Biogen position peaked at $3.01M in Q2 2013.
656 funds tracked by Wall St. Rank held Biogen as of Q3 2013.

Based on Traxis Partners's 13F filing for Q3 2013.